Indication

Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation

Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation is an endocrine management objective in women receiving exogenous gonadotropins during assisted reproductive technology procedures. Read more about Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation

12 drugs 11 manufacturers

Advertisement

Drugs that treat it

Common Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation therapies.

Showing 10–12 of 12 drugs

CETRORELIX ACETATE

LHRH(GNRH) ANTAGONIST, PITUITARY SUPPRESSANT AGENTS·PREVENTION OF LUTEINIZING HORMONE SURGE WHEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION
FRESENIUS KABI

GANIRELIX ACETATE

LHRH(GNRH) ANTAGONIST, PITUITARY SUPPRESSANT AGENTS·PREVENTION OF LUTEINIZING HORMONE SURGE WHEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION
FRESENIUS KABI

GANIRELIX ACETATE

LHRH(GNRH) ANTAGONIST, PITUITARY SUPPRESSANT AGENTS·PREVENTION OF LUTEINIZING HORMONE SURGE WHEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION
MULLAN PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation.

Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation is an endocrine management objective in women receiving exogenous gonadotropins during assisted reproductive technology procedures.

In this clinical state, developing ovarian follicles secrete rising levels of estradiol, which can exert positive feedback on the hypothalamic-pituitary-ovarian axis and provoke a premature spike in endogenous luteinizing hormone.

If uncontrolled, this premature surge triggers premature follicular luteinization and spontaneous follicular rupture, resulting in oocyte release prior to scheduled retrieval, compromised oocyte quality, and cycle cancellation.

Suppressive therapy maintains follicular development under exogenous control, permitting precisely timed maturation and successful transvaginal egg retrieval.

Personalize your experience

Follow Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it